Loading...
XNAS
ENTX
Market cap83mUSD
Jul 09, Last price  
1.70USD
1D
0.59%
1Q
47.83%
IPO
-73.02%
Name

Entera Bio Ltd

Chart & Performance

D1W1MN
XNAS:ENTX chart
P/E
—
P/S
1,995.08
EPS
—
Div Yield, %
—
Shrs. gr., 5y
20.19%
Rev. gr., 5y
-35.11%
Revenues
42k
-76.80%
000500,000236,000365,000571,000134,0000181,00042,000
Net income
-11m
L+19.89%
-4,282,000-1,199,000-11,197,000-10,304,000-10,795,000-11,216,000-12,187,000-13,071,000-8,889,000-9,541,000-11,439,000
CFO
-7m
L+8.10%
-3,495,000-3,142,000-4,526,000-9,796,000-8,919,000-10,557,000-9,063,000-12,499,000-7,310,000-6,818,000-7,370,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Entera Bio Ltd. is a biopharmaceutical firm in the clinical development phase, dedicated to creating and marketing oral medications composed of large molecules, addressing medical conditions that currently lack adequate treatments. Its primary experimental drugs are EB612, currently undergoing Phase II clinical assessment for hypoparathyroidism, and EB613, which has concluded Phase II studies for osteoporosis and is now in Phase I trials for treating non-healing bone fractures. Furthermore, the company holds a collaborative research and licensing pact with Amgen Inc. aimed at identifying and advancing potential therapeutic compounds for inflammatory conditions and other grave ailments. Established in 2009, Entera Bio Ltd. operates from its headquarters in Jerusalem, Israel.
URL
https://enterabio.com/
IPO date
Jun 28, 2018
Employees
19
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT